• IRLAB Therapeutics posted Q2 net sales of SEK 6.4 million, down 67.18% from the year-earlier period.
• Operating loss narrowed to SEK 16.7 million from SEK 25.7 million a year earlier.
• Loss per share improved to SEK 0.23 from SEK 0.62; cash fell to SEK 34.2 million at period-end.
• Completed a rights issue raising about SEK 76.5 million before costs; extended SEK 18.5 million of a Fenja Capital loan to Nov. 30, 2027.
• WHO assigned IRL757 the INN linepemat; first Phase Ib LIFT-PD results are expected in mid-2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IRLAB Therapeutics AB published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 202608260120ACCESSWRNAPR_____1212111) on August 26, 2026, and is solely responsible for the information contained therein.